Short Interest in Adlai Nortye Ltd. (NASDAQ:ANL) Increases By 21.5%

Adlai Nortye Ltd. (NASDAQ:ANL) was the recipient of a large increase in short interest in the month of June. As of June 15th, there was short interest totalling 13,000 shares, an increase of 21.5% from the May 31st total of 10,700 shares. Based on an average daily volume of 16,500 shares, the days-to-cover ratio is presently 0.8 days.

Adlai Nortye Price Performance

NASDAQ:ANL traded down $0.45 during mid-day trading on Friday, hitting $3.26. 2,493 shares of the company’s stock traded hands, compared to its average volume of 21,373. The firm has a 50 day moving average of $9.05 and a two-hundred day moving average of $8.97. Adlai Nortye has a 12 month low of $3.04 and a 12 month high of $19.30.

Institutional Trading of Adlai Nortye

A hedge fund recently raised its stake in Adlai Nortye stock. Cantor Fitzgerald L. P. lifted its stake in Adlai Nortye Ltd. (NASDAQ:ANL) by 128.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 40,310 shares of the company’s stock after buying an additional 22,644 shares during the period. Cantor Fitzgerald L. P. owned about 0.11% of Adlai Nortye worth $362,000 at the end of the most recent reporting period. 35.21% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Adlai Nortye in a research note on Thursday, June 20th.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.